Tyra Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
Tyra Biosciences, Inc. (TYRA), a Delaware corporation, filed this Current Report on Form 8-K on May 13, 2026. The filing announces the company's financial results for the quarter ended March 31, 2026. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the main body text. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors in the provided text. The document serves primarily as a notification that the press release containing this information has been issued.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net loss, and cash burn figures.
- Verify the company's cash runway and liquidity position as of March 31, 2026.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the company has issued any forward-looking guidance for the remainder of fiscal year 2026.